我是 LongbridgeAI,我可以總結文章信息。
- 2026 年 10 月 30 日,諾誠健華在中國完成了 ICP-B161 的 I 期臨牀試驗首例受試者給藥。 * 該雙特異性抗體靶向 TL1A 和 IL-23p19,用於潛在治療包括炎症性腸病在內的自身免疫性疾病。 * 臨牀前研究顯示,該藥物能顯著減輕結腸炎相關症狀,且耐受性良好。 * 其延長的半衰期支持更低頻率的給藥及皮下注射給藥方式。 * 目前全球尚無同時靶向 TL1A 和 IL-23p19 的雙特異性抗體獲批。 Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InnoCare Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610292201PRIMZONEFULLFEED9856744) on October 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)